NPI: 1619939071 · MARYVILLE, TN 37804 · General Acute Care Hospital · NPI assigned 04/03/2006
Authorized official LAWRENCE, KRISTI controls 20+ related entities in our dataset. Read more
| Authorized Official | LAWRENCE, KRISTI (DIRECTOR PROVIDER ENROLLMENT) |
| NPI Enumeration Date | 04/03/2006 |
Other providers sharing the same authorized official: LAWRENCE, KRISTI
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 48,100 | $2.44M |
| 2019 | 49,305 | $2.34M |
| 2020 | 42,911 | $2.12M |
| 2021 | 47,137 | $2.26M |
| 2022 | 39,684 | $1.97M |
| 2023 | 44,159 | $2.13M |
| 2024 | 29,627 | $1.49M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 36,166 | 34,044 | $7.38M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 23,486 | 22,495 | $3.49M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7,499 | 7,277 | $810K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,229 | 2,066 | $563K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6,469 | 6,080 | $405K |
| G0378 | Hospital observation service, per hour | 2,059 | 1,573 | $356K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5,448 | 1,562 | $248K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 43,727 | 40,097 | $206K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4,135 | 1,162 | $195K |
| 80053 | Comprehensive metabolic panel | 40,340 | 36,959 | $139K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 9,961 | 9,254 | $136K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1,142 | 1,080 | $108K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2,416 | 2,238 | $81K |
| 84484 | 6,122 | 4,399 | $63K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2,172 | 2,056 | $55K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 12,078 | 10,884 | $45K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 8,060 | 3,925 | $39K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,029 | 905 | $27K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4,356 | 4,058 | $26K |
| 84703 | 3,833 | 3,608 | $25K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3,525 | 2,532 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,655 | 2,408 | $22K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 121 | 116 | $20K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,874 | 2,659 | $19K |
| 71046 | Radiologic examination, chest; 2 views | 3,558 | 3,418 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 712 | 661 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 254 | 241 | $18K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 452 | 426 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2,674 | 2,599 | $18K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,241 | 2,063 | $17K |
| 81001 | 19,081 | 18,049 | $17K | |
| 70450 | Computed tomography, head or brain; without contrast material | 530 | 491 | $16K |
| 87400 | 2,113 | 1,016 | $12K | |
| 87081 | 2,249 | 2,184 | $10K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 38 | 36 | $10K |
| 97597 | 390 | 110 | $9K | |
| 83690 | 1,811 | 1,700 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,933 | 1,775 | $9K |
| 71045 | Radiologic examination, chest; single view | 3,536 | 3,296 | $8K |
| 95811 | 57 | 50 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 293 | 66 | $7K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 13 | 12 | $5K |
| 85610 | 4,064 | 3,132 | $4K | |
| 36415 | Collection of venous blood by venipuncture | 6,672 | 5,481 | $4K |
| 81025 | 1,419 | 1,365 | $4K | |
| 85730 | 1,316 | 1,235 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 94 | 85 | $4K |
| 83970 | 782 | 698 | $3K | |
| 83605 | 415 | 381 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 85 | 43 | $2K |
| 71250 | 93 | 73 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,389 | 1,329 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | 677 | 577 | $1K |
| 95816 | 14 | 14 | $1K | |
| 82728 | 321 | 292 | $779.95 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 12 | 12 | $668.75 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 15 | 15 | $635.74 |
| 94060 | 17 | 13 | $616.71 | |
| 84443 | Thyroid stimulating hormone (TSH) | 537 | 483 | $518.24 |
| 83550 | 296 | 268 | $475.03 | |
| 73630 | 47 | 40 | $468.87 | |
| 84702 | 23 | 13 | $440.91 | |
| 82607 | 220 | 201 | $378.42 | |
| 80069 | 525 | 466 | $370.81 | |
| 83540 | 296 | 268 | $345.17 | |
| G9162 | Spoken language expression functional limitation, current status at therapy episode outset and at reporting intervals | 75 | 65 | $334.56 |
| 94618 | 29 | 28 | $255.48 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 240 | 212 | $251.99 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 132 | 114 | $248.90 |
| 77300 | 25 | 12 | $240.60 | |
| 77334 | 16 | 12 | $232.78 | |
| 80061 | Lipid panel | 378 | 334 | $200.79 |
| 94729 | 29 | 25 | $198.76 | |
| 82746 | 122 | 114 | $168.86 | |
| 83735 | 38 | 36 | $132.64 | |
| 85027 | 15 | 13 | $119.72 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 15 | 13 | $95.28 |
| G9163 | Spoken language expression functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 75 | 65 | $83.64 |
| 87077 | 43 | 38 | $62.56 | |
| 94727 | 17 | 13 | $56.91 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 12 | 12 | $55.55 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 84 | 76 | $50.21 |
| 84481 | 53 | 51 | $48.65 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 4,327 | 4,084 | $35.26 |
| 84439 | 53 | 52 | $25.48 | |
| 81003 | 60 | 55 | $9.57 | |
| 87186 | 13 | 12 | $5.63 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 318 | 289 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 153 | 143 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 927 | 476 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 19 | 12 | $0.00 |
| 88304 | 14 | 13 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 262 | 214 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 15 | 13 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 127 | 109 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 27 | 26 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 29 | 27 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 15 | 15 | $0.00 |